Hosted on MSN9mon
Annexon spikes as lead asset hits main goal in late-stage studyWhile the 75 mg/kg dose tested in the study also outperformed placebo, its results were not statistically significant on the GBS-disability scale. Annexon (ANNX) said the experimental drug was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback